TG Therapeutics, Inc. - Common Stock (TGTX)
33.45
+0.28 (0.84%)
Tg Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various hematologic malignancies and autoimmune diseases
With a strong emphasis on targeted therapies, the company aims to improve patient outcomes through its proprietary drug candidates, which are designed to engage the immune system in a more effective manner. Tg Therapeutics is committed to advancing its research and development efforts to address unmet medical needs in these challenging therapeutic areas, leveraging the latest scientific advancements to enhance patient care.
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 15, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/14/A-Different-Picture.jpeg?width=1200&height=800&fit=crop)
TG Therapeutics Inc (NASDAQTGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024.
Via Benzinga · January 14, 2025
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 25, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill · November 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 21, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 29, 2024
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
Why TG THERAPEUTICS INC (NASDAQTGTX) qualifies as a high growth stock.
Via Chartmill · October 21, 2024
![](https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp)
Is TG THERAPEUTICS INC (NASDAQTGTX) suited for high growth investing?
Via Chartmill · October 15, 2024
![](https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp)
TG THERAPEUTICS INC (NASDAQTGTX) may be suited for growth investing, we'll explore why in this article.
Via Chartmill · September 30, 2024
![](https://cdn.benzinga.com/files/images/story/2023/options_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 12, 2024
![](https://www.investors.com/wp-content/uploads/2019/01/stock-NYSE-05-adobe.jpg)
A Fed rate cut and a slew of big earnings reports filled out a busy week.
Via Investor's Business Daily · November 8, 2024
![](https://www.investors.com/wp-content/uploads/2024/08/Stock-TGTherapeutics-01-shutt.jpg)
The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.
Via Investor's Business Daily · November 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/18/Medicine.jpeg?width=1200&height=800&fit=crop)
TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials.
Via Benzinga · September 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/04/movers-image_6.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 4, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/04/Apple--Nio--CVS-Health--Stellantis--Tesl.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 4, 2024
![](https://www.investors.com/wp-content/uploads/2023/01/Stock-metaverse-goggles-01-adobe.jpg)
Two of the 5 top stocks to watch this week tap the artificial intelligence market.
Via Investor's Business Daily · November 2, 2024
![](https://www.investors.com/wp-content/uploads/2020/10/Stock-NYSEbuilding-09-adobe.jpg)
Amid the election, and a Fed rate vote, earnings season roars ahead.
Via Investor's Business Daily · November 1, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
TG THERAPEUTICS INC (NASDAQTGTX) stands out as a growth opportunity that won't break the bank.
Via Chartmill · October 30, 2024
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
TG THERAPEUTICS INC (NASDAQTGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill · October 15, 2024
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill · October 9, 2024
![](https://cdn.benzinga.com/files/images/story/2023/options_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 23, 2024
![](https://www.investors.com/wp-content/uploads/2018/12/Stock-NYSE-09-adobe.jpg)
TheApple iPhone 16 went on sale amid mixed signals about demand.
Via Investor's Business Daily · September 20, 2024